Ida Kjær

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

Klaus Koefoed, Lucilla Steinaa, Josefine Nielsen Søderberg et al. · mAbs · 2011 · 92 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

Helle J. Jacobsen, Thomas T. Poulsen, Anna Dahlman et al. · Clinical Cancer Research · 2015 · 84 citations

Medicine, Oncology, Pharmacology +16

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

Mikkel W. Pedersen, Helle J. Jacobsen, Klaus Koefoed et al. · Molecular Cancer Therapeutics · 2015 · 53 citations

Pharmacy, Oncology, Pharmacology +17

Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures

Ida Kjær, Trine Lindsted, Camilla Fröhlich et al. · Molecular Cancer Therapeutics · 2016 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space

James Longden, Xavier Robin, Mathias Engel et al. · Cell Reports · 2021 · 14 citations · Full text

Life Sciences, Cell Biology, Oncology +16